Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy

• Published in: The AAPS journal 2021-06, Vol.23 (4), p.90, Article 90
• Main Authors: Varshney, Dhruv, Qiu, Sherry Yue, Graf, Tyler P., McHugh, Kevin J.
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - administration & dosage; Antineoplastic Agents - chemistry; Biochemistry; Biomedical and Life Sciences; Biomedicine; Biotechnology; Drug Delivery Systems - methods; Humans; Neoplasms - drug therapy; Neoplasms - immunology; Pharmacology/Toxicology; Pharmacy; Review Article; Solubility; Theme: Rising Stars in Drug Delivery and Novel Carriers; Toll-Like Receptor 7 - agonists; Toll-Like Receptor 8 - agonists
• ISSN: 1550-7416; 1550-7416
• DOI: 10.1208/s12248-021-00620-x

Toll-like receptors (TLRs) are a potential target for cancer immunotherapy due to their role in the activation of the innate immune system. More specifically, TLR7 and TLR8, two structurally similar pattern recognition receptors that trigger interferon and cytokine responses, have proven to be therapeutically relevant targets for cancer in numerous preclinical and clinical studies. When triggered by an agonist, such as imiquimod or resiquimod, the TLR7/8 activation pathway induces cellular and humoral immune responses that can kill cancer cells with high specificity. Unfortunately, TLR7/8 agonists also present a number of issues that must be overcome prior to broad clinical implementation, such as poor drug solubility and systemic toxic effects. To overcome the key limitations of TLR7/8 agonists as a cancer therapy, biomaterial-based drug delivery systems have been developed. These delivery devices are highly diverse in their design and include systems that can be directly administered to the tumor, passively accumulated in relevant cancerous and lymph tissues, triggered by environmental stimuli, or actively targeted to specific physiological areas and cellular populations. In addition to improved delivery systems, recent studies have also demonstrated the potential benefits of TLR7/8 agonist co-delivery with other types of therapies, particularly checkpoint inhibitors, cancer vaccines, and chemotherapeutics, which can yield impressive anti-cancer effects. In this review, we discuss recent advances in the development of TLR7/8 agonist delivery systems and provide perspective on promising future directions.